STAY SEC PsO: A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy (clinicaltrials.gov) - Oct 20, 2026 - P=N/A | N=3718 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New trial • Dermatology • Immunology • Psoriasis
|